sign in sign up
<<
Home , Zatosetron

AUTHOR INDEX

Abbott, Frank S., 284, 415, 889, Boersma, M. G., 218 Cooney, David A., 369, 738 Faudskar, A. Lawrence, II, 902 1098 Bogdanffy, Matthew S., 1107 Correia, Maria A., 730 Favreau, L., 861 Abdel-Rahman, Mohamed S., 788 Bolton, Mary G., 986 Coulombe, Roger A., Jr., 555 Feil, V. J.,624 Abeysinghe, R. D., 640 Bongard, Robert D., 428 Cravedi,J.P.,377 Feng,R., 1119 Abiteboul, Michel, 617 Bonnafous, M., 811 Cretton, Erika M., 946 Fenselau, Catherine, 91 1 Abramson, Fred, 868 Bopp, Barbara A., 805 Cribb, Alastair E., 520 Ferguson, Nikita I., 745 Adam, Albert, 485 Borel, Anthony G., 415, 889 Criscuoli, Marco, 835 Fernandez, C., 1125 Adedoyin, A., 184 Bouchard, Line, 293 Ferraiolo, Bobbe, 71 Adusumalli, Vidyasagar E., 710, Boudinot, F. Douglas, 855 Dam, Jeremy 0., 567 Forkert, P. Gek, 770 1079 Boutin,JeanA., 1157 Daley-Yates, P. T., 100 Fornasini, Gianfranco, 933 Dalton, James 1., 544 Ahluwalia, Gurpreet, 369, 738 Bradbury, A., 761 Fournel-Gigleux, Sylvie, 617 Damani, Lyaquatali A., 255 Aksoy, I. A., 268 Breau,AlanP., 162,249 Franklin, L. Karen, 951 Dandekar, Kishor A., 447 Alberts, David W., 1029 Brendel, Klaus, 454 Franz, Paula M., 249 Albrecht, E., 818 Brenner, Dean E., 277 Das, Mukul, 194 Fredenburg, Andrea M., 255 Davis, Patrick J.,259 Allievi,C., 151 Brett,Claire M., 587 Fridland, Arnold, 369 Davis, Richard A., 788 Alton, Kevin B., 198 Broder, Samuel, 369 Friedman, Marvin A., 788 Anders, M. W., 634 Brouwer, Kim L. R., 1129 Dawson, Christopher A., 428 Fu, Emil, 567 Day, Wesley W., 474 Andoh, Katashi, 1142 Burchell, Brian, 50 Fujioka, M., 971 Andrew, P. D., 761 Burka,LeoT.,9l8 Debrauwer, L., 377 Fujita, Shoichi, 1012 D#{233}chelotte, Pierre, 13 Arisen, B. H., 670 Fujitsu,T., 971 Dedinas, John, 911 Aristorena, Juan-Carlos, 215 Cal, Yong, 605 Fung, Ho-Leung, 967 Arvidsson, Annie, 171 Canali, Sergio, 144 Defrance,S., 811 Gachon, F., 560 Au, Jessie L-S., 544 Cano, Jean Paul, 338, 823 de Goeij, Jeroen J. M., 30 Gaillard, 0., 560 Audibert, 0., 7 Cashman, John R., 492, 587, 753 Delaporte, Enock, 520 Delous, G., 377 Gandolfi, A. Jay, 386 Axelson, James E., 284 Castelli,M.G., 151 DeLuna, Florencia A., 800 Garcia-Carbonell, Maria C., 215 Castle,M.C., 1147 Gelboin, Harry V., 645 Babe, Takahiko, 1048 Castonguay, Andre, 293, 318 De Maack, F., 939 Gerig,J.T., 105 Bath, Mostafa Z., 305 Catalin, Jacques, 338, 823 Deremer, Susan J., 277 DeSante, Karl A., 249 Geurtsen, Bail, 508 Bai, Stephen A., 156 Chadwick, Majory, 209 Ghanayem, Burhan I., 209 Bailey, John R., 364 Championsmith, Antonio, 71 DiLea, C., 662 Giachetti, Antonio, 835 Baillie, Thomas A., 242, 580 Chan, Tze-Ming, 198 Dixon, C. M., 761 Giacomini, Kathleen M., 587 Baker, David C., 738 Chang, A. S., 125 Dogterom, Peter, 699, 705 Gilbert, P. J., 1037 Baker,MaxT.,299, 1170 Chang, Tsun, 874, 1112 Donahue, Brian S., 745 Dorman, Douglas E., 249 Gimenez, F., 1125 Balani, Suresh K., 598 Chauret, Nathalie, 861, 1029 Gires, P., 997 Baldew, Glenn S., 30 Chay, Sylvia H., 162 Doroudian, Ahmad, 284 J.,855 Godeneche, D., 93, 560 Bandyopadhyay, Abhik M., 782, Chen, 1.-Wu, 800 Doshi, Kokila Godin, C. 5., 551 1064 Chen, teng-Man, 480 Drerup,J.M., 551 Goehl, Thomas J., 189 Barbhaiya, Rashimi H., 447, 502 Chenery,R.J., 18 Drey,JustinaM., 861, 1029 God, 0. P., 874 Barrow,A., 1022 Cheng, Xiaoqin, 121 Dubois, Nathalie, 617 Goldberg, Mark J., 249 Batt, A. M., 939 Chesa-Jim#{234}nez, Jesus, 215 Duffel, Michael W., 400 Goldman, Mark E., 598 Battagjia,R., 151 Chiang, Chao-Kuo, 1170 Duggan, Daniel E., 1003 Gomez, Denise Y., 587 Bekersky, Ihor, 1017 Chiba, Kan, 747 Duhart, Helen M., 364 Dumont, Louis, 485 Gonzalez, Frank J., 1048 Bend, John R., 334 Chikai, Toshiyuki, 542 Gorski, John, 567 Benedetti, M. Strolin, 151 Chisena, Christine, 738 Duncan, C. A., 467 Durand, Alain, 338, 823 Granero, Luis, 215 Benet, Leslie Z., 730 Chiu, Shuet-Hing L., 670, 792 Granneman, G. Richard, 805 Benincosa, Lisa Jo, 750 Cho,A.K., 125 Durham, Sherrie L., 480 Griffin, Robert J., 918 Berger, H., 818 Choi,Y.M.,710 du Souich, Patrick, 7, 485 Grossman, Scott J., 1029 Berger, Yves, 978 Chou, Chen-Hsi, 933 Dusterberg, B., 203 Grossman, S. J.,861 Bernadou,J., 811 Chow, Fung S.,690 Ebner, Thomas, 50 Guengerich, F. Peter, 1, 403, 1048 Bertin, Didier, 1157 Chu, Chung K., 855 Eddy, A. Craig, 309 Bezek, Stefan, 547 ChUi,Y.C., 1119 Edwall, BjOm, 171 Hackbarth, Ingeborg, 13 Bienvenu, Thierry, 178 Chung,JungG., 1057 Ehlhardt, William J., 162 Hall, Caroline, 284 Biggi, Wendy A., 454 Chung, Suk-Jae, 967 Ehninger, Gerhard, 955 Hall, Stephen D., 114 Binienda, Zbigrnew, 364 Clarke, S. E., 18 ElDareer,SalahM., 231 Hall,TseW., 133 Birch,GaryM., 162 Qement, Bmd, 24 Elfarra, Adnan A., 841 Halpin, Rita A., 1003 Bishop, Jack B., 1091 Cnubben, N. H. P., 218 Elliott, J. M., 467 Hamilton, Robert, 1172 Bjorge, Susan M., 874 Coddington, Arthur B., 1086 Ensminger, William D., 277 Hanson, Glen, 1017 Black,Ann, 1112 Coe, R. A. J., 1037 Eugster, Hans-Pietro, 43 Hao, Zhang, 738 Blackburn, R. Kevin, 573 Colby, Howard D., 200, 1086 Evans, Allan M., 933 Harbison, Raymond D., 537 Bland, T. J., 530 Colthup, P. V., 1022 Harrell, A. W., 18 Blanz, Joachim, 955 Colvin, 0. Michael, 986 Fabre, Gerard, 978 Hartley, T. E., 1037 Blom, M., 218 Connors, Suzanne, 454 Falkner, K. Cameron, 334 Hartman, Neil R., 369 Blown, Robert A., 782, 1064 Cook, C. Edgar, 717 Farinotti, R., 1125 Hasegawa, Takaaki, 611 Boeren, Sjef, 508 Cook, Jennifer, 71 Farooqui, Mohammed Y. H., 460 Hasinoff, Brian B., 883

1175 1176 AUTHOR INDEX

Hatcher, Barbara L., 249 Kato, Katsuyoshi, 611 Magdalou, Jacques, 617 Nicoletti, Joseph, 567 Hebbler, Anna K., 738 Kato, Nobuo, 611 Manabe, Kyoko, 747 Nicoll-Griffith, Deborah A., 861, Heinrich,N., 811 Kauffman, Laura. R., 598 Manchee, G. R., 1022 1029 Hendrickx, Jan, 1134 Kaul, Sanjeev, 447 Mani, Chitra, 645, 657 Nijmeijer, Sandra M., 441 Hennig, Philppe, 1157 Kehrer, James P., 37 Mams, Melanie, 181 Noda, K., 971 Herold, E., 861 Keller, Deborah A., 911 Mannens, Geret, 1134 Noe, Dennis A., 986 Herold, Eugene G., 1029 Kelley,JamesA., 738 Mantlo, N. B., 670 Nomeir, Amin A., 209 Heykants, Joseph, I 134 Kertscher,U., 818 Maradeix,V., 1125 Noordhoek, Jan, 441 Hezari, Mehri, 259 Khanna, Subhash K., 194 Marathe, P. H., 502 O’Brien, Julie A., 598 Hichens, M., 467 Kharasch, Evan D., 350 Markham, Peter M., 209 Occolowitz, John L., 249 Hider, R. C., 640 Kim, Myungsoo, 309 Marshall, M. L., 640 Oehlke, J., 818 Hider, Robert C., 255 Kimura, Toshikiro, 677 Martdll, Karen J., 965 Higuchi, Saburo, 524 Kitada, Mitsukazu, 358, 777 Martin, Ulrich, 236 Ohmori, Shigeru, 358, 777, 1048 Ohnishi, Noriaki, 141 Hill, Donald L., 231 Kjaassen, Curtis D., 342 Martinet, M., 997 Okereke, Chukwuemeka S., 788 Hill,Judith M., 717 Knutsen, Conrad A., 277 Maskasame, Chaiyasit, 156 Okerholm, Richard A., 403 Hilibeck, D., 1037 Kobayashi, Kaoru, 747 Mason, William D., 305 Okumura, Katsuhiko, 141 Hilton, John, 986 Komada, Fusao, 141 Masubuchi, Yasuhiro, 1012 Olah, Timothy V., 598 Hinderling, P. H., 662 Komiya, Moriyoshi, 777 Mather, Laurence E., 1151 Olive, Georges, 178 Hinton, Melvin L., 62 Kosanke, Stanley D., 605 Maton, N., 850 Olsen, George D., 390 Hiramatsu, M., 125 Kowaluk, Elizabeth A., 967 Matsubara, Takashi, 542 Olsen, Mark A., 911 Hirose, Seiyu, 358 Koziol, T., 662 Mattiuz, Edward L., 249 Ong, Huy, 485 Hodgson, Ernest, 657 Krause,W., 203,682 Maurice, Marie-Helene, 617 Otterness, D. M., 268 Hoffmann, Kurt-Jurgen, 435 Krejcy, K., 962 Mayersohn, Michael, 1091, 1172 Ottoila, Pekka, 81 Hoke, John F., 480 Kucharczyk, Norbert, 7 10, 1079 McCague,R., 1119 Oxford, J., 761, 1022 Homnick, C. F., 467 Kuhne, G., 682 McCallum, Gordon P., 334 Horeck, J., 962 Kukan, Mari#{227}n,547 McClain,CraigJ., 1064 Page, John G., 189 Hoyer, G.-A., 203, 682 KUlkarni,S., 1022 McClure, Harold M., 855 Palmer, B. D., 530 Hu, Pci, 580 Kunze, Kent L., 350, 874 McLean,ColinF., 1151 Palmer, E., 1022 Huang, May-Lynn, 1134 Kupfer, David, 645, 657 McNally, William, 1 1 12 Pang, K. Sandy, 1070 Huggins, John W., 555 Kuriya, Shin-Ichiro, 358 McVie, J. Gordon, 30 Papon,J.,93,560 Hwe, J. Michael, 555 Kwan, Eddie, 284 Melus, Mikul#{225}s,547 Park, Sang B., 587 Hunninghake, Donald B., 1003 Kyerematen, Gabriel A., 927 Mengozzi, Grazia, 835 Park, Sang S., 645 Huskey, Su-Er W., 792 Labarre, P., 93, 560 Meuldermans, Willem, 1134 Parkinson, Andrew, 645 Hussein, Ziad, 805 Meunier, B., 8 1 1 Patel, Dipak K., 62 Huwe, J. K., 624 Lacarelle, Bruno, 338, 823 Ladd, David L., 911 Meunier, Florent, 1157 Patetta, Patricia K., 717 Hwang, In Young, 841 Laizure, S. Casey, 951 Miller, Mario, 951 Patrick, Darryl H., 1029 Miller, Randall R., 670, 792 Paule, Merle G., 364 Inui, Yukihara, 1048 Lake-Bakaar, Desmond, 171 Millington, G., 662 Paulson, G. B., 624 Irwin, Richard D., 189 Lambert, Pierre.-Herv#{234}, 1157 Milne, Robert W., I151 Paxton, J. W., 530 Ishii, Itsuko, 358 Lanbeck-Vallen, Kerstin, 171 Mimura, Mayumi, 1048 Pearce, Robin, 645 Ishizaki, Takashi, 747 Landaw, E. M., 125 Pennick, M., 18 Iwakawa, Seigo, 141 Lankford, Susan M., 156 Mitchell, David Y., 342, 396 Perez-Reyes, Mario, 717 Iwasaki, K., 971 Lapicque, Francoise, 617 Mitsuya, HirOaki, 369 Peris-Ribera, Jos#{233}-Esteban, 215 Iyer, Krishna R., 902 Larrauri, Aamparo, 454 Mohammed, N., 640 Larson, Irena W., 200 Mohler, Maijorie, 71 Perno, Carlo-Federico, 738 Jakobs, U., 203, 682 Le Cotonnec, Jean-Yves, 144 Mong, Seymour, 1017 Perreault, Sylvie, 485 Perry, James, Robert C., 537 Lee,Helen, 1112 Moore, Jerome, 71 P. R., 184 James, Ruby H., 189 Lee, P., 640 Mordenti, Joyce, 71 Petersen, Dennis R., 396 S.,474 Jarman,M., 1119 Lennernas, Hans, 435 Moreau, M. F., 93, 560 Piatkowski, T. Piekoszewski, Wojiech, 690 Jayyosi, Z., 939 Levitt, Miriam, 200 Morgan, Edward T., 745 Jeffcoat, A. Robert, 717 Levy,GeraldN., 1057 Morris, Marilyn E., 750 Piotrovskij, V. K., 962 Jenden, D. J., 125 Lewis, Derf, 71 Mousse, Madeleine, 770 Piper, John, 460 K. A., Johns, David G., 369, 738 Lewis, Rebecca P., 62 Muindi, J. F., 410 Pittman, 502 Johnson, Norma J., 277 Lho#{235}st,G.,850 Mulder,GerardJ., 1070 Pitzenberger, Steven M., 467, 598 Johnson, Robert L., 62 Lin, Jiunn H., 800 Mulford, Darcy I., 805 Pl#{225}-Delfina,Jos#{233}M., 215 Johnston, Michael R., 428 Lind, Richard C., 386 Murphey, Lame J., 390 Podoll, Terry, 350 Pongchaidecha, M., 100 Jorquera, Rossana, 318 Linehan, John H., 428 Murphy, Constance M., 911 Joyeux, Henri, 978 Lipa, Joan, 56 Musser, Steven M., 738 Pons, Gerard, 178 Julian, Bernard, 978 Lippi, Annalisa, 835 Pool, William F., 874 Nabeshima, Toshitaka, 611 Jusko, William J., 690 Loiseau, P., 811 Poon,G.K., 1119 Nadai, Masayuki, 611 Loizou, George D., 634 Porchet, Herv#{233}C., 144 Kathy, Abdelrazak M., 788 Nagase, K., 971 Lonning, P. E., 1119 Porter, J. B., 640 Kagimoto, Nonko, 1012 Nakano, Masyuki, 542 Los, Gerrit, 30 Posey, Claude F., 231 Kaiser, David G., 951 Nakasa, Hiromitsu, 777 Los, Layne E., 1086 Pramanik, Birendra, 198 K#{225}llay,Z., 962 Nakatsuka, Iwao, 1167 Lustig, Kiemens L., 24 Prejean,J. David, 189 Kanakubo, Yoshio, 358 Narimatsu, Shozuo, 1012 Pritchard, Mike, 617 Kanekal, Sarathchandra, 37 Maconochie, J. G., 1022 Nation, Roger L., I 151 Probst, Markus, 43 Kari, Prasad H., 467, 1003 Madelmont, J. C., 93, 560 Nelson, Wendel L., 309 Prome, D., 377 Kassahun, Kelem, 242, 1098 Madhu, Cherukury, 342 Netter, Patrick, 617 Pmeksaritanont, Thomayant, 730 AUTHOR INDEX 1177

Pugh, Dorothy E., 717 Schmid, Christopher R., 249 Tani, Masayoshi, 747 Vyas, K. P., 467 Puhl, R. James, 1017 Schmitz,DebraA., 125 Tamguchi, Tomoyoshi, 358 Walle, T., 76 Purchase, Claude F., II, 874 Schorn, Terry. W., 598 Tarbit, M. H., 761, 1022 Walle, U. K., 76 Schroeder, David H., 62 Taskinen, Jyrki, 81, 325 Walters, Karen M., 305 Quijano, Romeo F., 141 Schroeder, Mel C., 874 Taylor, Marie L., 1107 Wang, Li, 611 Schuller, Hildegard M., 318 Taylor, Wesley G., 133 Raberger, G., 962 Wang, Ying, 299 Schwenk, Michael, 13 Tenney, Kirsten A., 745 Rajaonarison, Jean-Francois, 338, Warrell, Raymond P., Jr., 410 Seaton, Mark J., 927 Teramura, Toshio, 524 823 Washington, Carla B., 587 Sengstag, Christian, 43 Terrio, Patricia A., 277 Ramamurthy, S., 125 Watanabe, Takashi, 524 Serkiz, Bernard, 1 157 Theoharides, Anthony D., 598 Ramjit, Ham G., 598, 1086 Weber, Wendell W., 181, 965, Sharma, Raghubir P., 555 Thiroux, Genevieve, 178 Rapp, M., 93 1057 Shear, Neil H., 830 Thomas, Paul E., 730, 939 Redureau, M., 997 Wedlund, Peter J., 255 Shedlofsky, Steven I., 1064 Thomassin, J., 151 Reg#{227}rdh,Carl-Gunnar, 435 Weiner, Myron, 474 Shen, Danny D., 309 Thornburg, K. R., 76 Remmel, Rory P., 902 Weinshilboum, R. M., 268 Shimada, Tsutomu, 1048 Thuillier,A., 1125 Renberg, Lars, 435 Wheeler, S. M., 18 Shimatani, K., 971 Thummel, Kenneth E., 350 Renner, Ulf, 955 Wheeler, William J., 162 Shipley, Lisa A., 753 Till,AliceE., 1003 Renton, Keeneth W., 520 White, W. Reid, 717 Shiraga, T., 971 Tillery, Kathleen F., 231 Rettie, Allan E., 730 Wichmann, Joseph K., 710, 1079 Shirley, Michael A., 580 Tinker, John H., 1170 Rey, Elisabeth, 178 Wikberg, Tom, 8 1, 325 Shockcor, John P., 62 Toler, Steven M., 1064 Rietjens, Ivonne M. C. M., 218, Wilkinson, G. R., 184 Shono, Fumiaki, 1167 Torres-Molina, Francisca, 215 508 Williams, Cheri L., 951 Shukla, Umesh A., 447, 502 Tozuka, Z., 971 Rikans, Lore E., 605 Williams, Theresa M., 598 Shum,Y.Y., 1112 Tracy, Timothy S., 114 Rikihisa, Tadaaki, 358, 777 Winter, Steven M., 1091 Shyu, Wen C., 447 Trager, William F., 874 Roberts, Eve A., 56 Wirthwein, Darren P., 114 Siest, Gerard, 617, 939 Trang, John M., 189 Roberts, Stephen M., 537 Witkamp, Robert F., 441 Sigel, Carl W., 62 Trimble, L. A., 861 Robertson, I. G. C., 530 Woestenborghs, Robert, 1134 Singh, S.,640 Trnovec, T., 962 Robertson, Keith D., 986 Wong, K. K., 710 Sinicropi, Dominick, 71 Troke, J. A., 1037 Robertson, LaiTy W., 782 Woolf, Thomas F., 547, 874, 1112 Sipes, I. Glenn, 1091 Turcan, R. G., 1037 Roerig, David L., 428 Wrighton, Steven A., 492, 753 Skinner, Thomas L., 255 Tyrakowska, Bozena, 508 Romanyshyn, L. A., 710 W#{252}rgler,Friederich E., 43 Slikker, Jr., William, 364 Ronnenberg, William C., Jr., 1170 Uchida, Taisuke, 524 Sloan,PaulA., 1151 Xie, Zhang, W., 56 Rooney, Clarence S., 598 Uetrecht, Jack P., 830 Smith, David E., 277 Rose, Lucy M., 231 Ulm,EdgarH., 1003 Yabuki, Masashi, I 167 Smith, D. J., 624 Rosegay,A., 670 Umbenhauer, Diane R., 1029 Yamazaki, Hiroshi, 1048 Smith, J. L., 670 Rosenberg, Daniel W., 846 Umeda, Kayo, 141 Yang, Lihong, 492 Smith, Steven J., 598 Rothuizen, Jan, 705 Usui, Takashi, 524 Yang, Suyun, 56 Snel, C. A. Wilco, 1070 Rowland, Malcolm, 933 Yang, Zi-Chen, 587 Sofia, R. Duane, 710, 1079 van Berkel, W. J. H., 218 Rowlands,M.G., 1119 Yang, Zicheng, 492 Sommadossi, Jean-Pierre, 946 Van Breemen, Richard B., 573 Rubin, Alan, 249 Yarchoan, Robert, 369 Somogyi,AndrewA., 1151 VandenBranden, Mark, 753 Runciman, William B., 1151 Ybarra, Benjamin, 460 Song, Hengchang, 868 Van Miert, Adelbert S. J. P. A. M., Rurak, Dan W., 284 Yeleswaram, Krishnaswamy, 284 Soria, Imaculada, 724 441 Ruth, James A., 121 Yergey, James A., 86 1, 1029 Sparadoski, R. E., Jr., 710 Varga, Sandor L., 598 Rutten, Albert J., 1151 Yisak, Wolde, 171 Sponer, Gisbert, 236 Vedres, Darrell D., 133 Ruzicka,JanA., 1170 Yorkel, Robert A., 255 Stearns, R. A., 670 Venkataraman, Pankaja S., 605 Yoshida, Toshiaki, 1142 Sabouraud. Alain, 13, 997 Stetson, PhilipL.,277 Verbeeck, R. K., 850 Yoshitake, Akira, 1167 Sadler, Brian M., 717 Stevens, Jeffry C., 753 Vermeulen, Nico P. E., 30 Young, A. Bryon, 1064 Saint-Aubert, Bernard, 978 Stevens, Robert C., 951 Vervoort, J., 218 Young, Charles W., 410 Sakuma, S., 971 Stevens, Yee-Wan, 410 Vesell, Elliot S., 927 Yun, Chul-Ho, 403 Sandberg, Jennifer, A., 390 Stiller, Steven W., 231 Vestling,MarthaM.,9ll Yun, Hyoin, 441 Sanders, Paula L., 951 Stowe, Emily E., 738 Veyre, A., 93,560 Sandouk, Pierre, 13 Streeper, Robert T., 986 Vickers, Alison E. M., 454 Zahid, Nasir, 830 Sandow,J., 811 Strein, Klaus, 236 Vickers, S., 467 ZaInbOni, R., 861 Sardelli, Giuliana, 835 Struck, Robert F., 231 Vidal,M.,8l1 Zannikos, Peter N., 782 Sato, A., 971 Subissi, Alessandro, 835 Vilhiere, Valerie, 485 Zanolo, Giovanni, 144 Saumer, C. G., 7 Suzuki, Akira, 677 Villoutreix, J., 939 Zeller, Klaus-Peter, 955 Sawamoto, Taiji, 677 Suzuki, Tokuji, 1012 Vinegar,A., 551 Zhao, Ying, 1070 Saynor, D. A., 761 Swinney, David C., 730 Vogelaar, John P. W., 454 Zheng, Wei, 1091 Scallen, Terence J., 567 Sylvia, L. A., 105 Voice, Ronald A., 181 Zheng, Yuqun, 400 Scherrmann, J. M., 997 Volland, Jean-Paul, I 157 Ziegler, Daniel M., 24 Schey, K. L., 76 Tabuchi, Takeo, 1142 Vose,C.W., 1037 Ziegler, J. M., 939 Schinazi, Raymond F., 855 Tanaka, Yoshio, 677 Vuorela, Aija, 81 Zimmerman, Cheryl L., 724,902 Schmeer, Karl, 955 Tandon, Sangita, 194 Vyas. Kamleash P., 1003 Zollinger, Markus, 454 SUBJECT INDEX

Acetaminophen, disposition of metabolites, acute admin- 3’-Azido-2’,3’-dideoxy-5-methylcytidine, pharmacokinetics and metab- istration (rats), 1129 olism (monkeys), 855 Acetyl coenzyme A-cholesterol acyltransferase inhibitor, metabolic N- 3’-Azido-2’,3’-dideoxynucleosides, reduction to 3’-amino metabolite, demethylation (rats), 524 cytochrome P-450 and NADPH-cytochrome P-450 reductase, N-Acetyltransferase liver microsomes (rats), 946 p-aminobenzoic acid, distribution of 2-aminofluorene, tissues of rapid 3’-Azido-3’-deoxythymidine, glucuronithtion, effect of anticancer drugs, and slow acetylators (mice), 1057 liver microsomes (humans), 823 red blood cell, inhibition of(humans), 181 , homologous series, lipophilicity and hepatic dispersion, Acridine carboxamide, metabolism (mice), 530 liver(rats),933 Acyl-coenzyme A:cholesterol acyltransferase, inhibitor 2,2-dimethyl-N- l,5-, metabolic profiling ofclobazam (rats), 415 (2,4,6-thmethoxyphenyl)dodecanamide, biodisposition studies Benzophenone-3, metabolism (rats), 788 (rats,monkeys), I 112 Benzoylecgonine, metabolism of , inhibition by ethanol (mice, Adrenal gland, microsomal monooxygenases, zonal differences, thermal humans), 537 lability (guinea pigs), 200 Bernard B. Brodie Award, bioactivation and detoxification, toxic and Aging, redox cycling and hepatotoxicity (rats), 605 carcinogenic chemicals, 1 Albuterol, stereoselective sulfation (humans), 76 Biantrazole, detection and identification, urinary metabolites (humans), Aldehyde dehydrogenases, liver mitochondrial and cytosolic, inhibition 955 by crotonaldehyde (rats),396 Bile Alendronate, uptake by bone tissue, hypocalcemia and hypercalcemia excretion ofglutathione and hydrolysis products, P-450 inducers (rats), (rats), 800 342 Allylnitrile, toxicokinetics (rats), 460 glucuronidation as transient intermediate metabolic step, elimination Amines, tertiary, stereo- and regioselective N- and S-oxidation, liver ofcarbovir (rats), 902 microsomes (humans), 492 rates of excretion, cotinine, glucuronide and 3-hydroxycotin- p-Aminobenzoic acid, N-acetyltransferase activity in tissues, distribution, inc (rats), 927 rapid and slow acetylators (mice), 1057 1,2-Bis(2,4,6-tribromophenoxy)ethane, disposition following administra- 2-Aminofluorene, p-aminobenzoic acid N-acetyltransferase activity and, tion in diet (rats), 209 tissues, C57BL/6J rapid and B6.A-Nai’ slow acetylator congenic 1,3-Bis[[1-cycloheptyl-3-(P-d.imethylaminophenyl)ureido)methyl)ben- mice, 1057 zene dihydrochlonde, metabolic N-demethylation (rats), 524 3-Amino-l-phenylbutane, disposition and metabolism, pharmacody- Bisphosphonates, pamidronate, 4-hour and 24-hour infusions, clearance namics oflabetalol (sheep), 284 and tissue uptake (rats), 100 Amiodarone, CYP3A-mediated N-deethylation, liver microsomal frac- 3-Blockers, pafenolol, pharmacokinetics and metabolism (rats, humans), tions (humans), 978 435 Androgens, biotransformation and branchial excretion, 17a-methyltes- BM 006.022, pharmacokinetic properties, influence, hepatic and renal tosterone (fish), 377 failure (rats), 236 Anesthetics, biotransformation, concentration-dependent in- Bone, uptake of alendronate, hypocalcemia and hypercalcemia (rats), hibition (guinea pigs), 386 800 Antianxiety agents, zatosetron disposition (humans), 249 Brain Antiarrhythmic agents, class III, metabolism studies (dogs), 467 distribution of felbamate (rats), 1079 Antibiotics, cefadroxil, nonlinear pharmacokinetics (rats), 215 tirilazad disposition (rats), 951 Anticancer drugs, glucuromdation of 3’-azido-3’-deoxythymidine, liver Breast neoplasms, phase I and phase II metabolites, (humans), microsomes (humans), 823 1119 Anticonvulsants, felbamate, distribution to cerebrospinal fluid and brain Bromodeoxyuridine, 5-fluorouracil or iododeoxyuridine, mutual kinetic (rats),1079 interaction (dogs), 277 , DL-rolipram, biotransformation, metabolites from wine Bromosulfophthalein, localization of glutathione conjugation activities, (rats, monkeys, humans), 682 perfused liver (rats), 1070 Antiinfective agents, 1,3-di(4-imidazolino-2-methoxyphenoxy)propane, Bronchodilators, salmeterol xinafoate, disposition (rats, humans), 1022 disposition (rats), 1017 Buserelin, disposition (rats), 818 Antiviral agents Butadiene, metabolites, methodology for quantitation, liver microsomes carbocycic 3-deazaadenosine pharmacokinetics (mice), 555 (rats),121 l,3,4-thiadiazol-2-ylcyanamide, biotransformation (mice), 162 Argemone, alkaloid sanguinarine, biometabolic elimination, organ reten- estradiol and , interaction with CYP1AI and CYP1A2, tion profile (rats, guinea pigs), 194 Saccharomyces cerevisiae (human), 43 Arsenite, effect on NAD(P)H:quinone acceptor oxidoreductase activity, metabolism in liver slices, postnatal development (rats), 178 liver and lung, heart and kidney (rats), 334 Calcium, antagonist SM-6586, cleavage, 1,2,4-oxadiazole ring, 1167 Aryl sulfotransferaselV, hepatic, naphthaldehydesas reversible inhibitors 3-Carbamoyloxy-2-phenylpropionic acid, major urinary metabolite of (rats),400 felbamate (humans), 710 Assays Carbocycic 3-deazaadenosine, pharmacokinetics (mice), 555 immobilized digestive enzyme, chemical and enzymatic hydrolysis, Carbovw lysobactin, 573 disposition in the in situ perfused liver, intestinal vasculature prepa- simplified methodology for quantitation, butadiene metabolites (rats), rations (rats), 724 121 glucuromdation, transient metabolic step (rats), 902 , gastrointestinal motility, bioavailability of cyclosporine A Carboxylesterase-mediated metabolism of vinyl acetate, kinetics (rats), (rats),141 1107 1178 SUBJECT INDEX I 179

Carboxylic acids, 4-ene VPA and 4-pentenoic acid, reactive metabolites, CYP1A1, specificity of verlukast epoxidation (mice, rats, monkeys, hu- thiol conjugates, 1098 mans), 1029 Carcinogens CYP2B, induction of enzymes, nutritional obesity, phenobarbital treat- characterization of cytochrome P-450 2B6, liver microsomes (hu- ment (rats), 782 mans), 1048 CYP3A-mediated N-deethylation of amiodarone, liver microsomal frac- metabolism ofmethylnitrosamino1-(3-pyridyl)-l-butanone, inhib- tions (humans), 978 itory effects ofNSAIDs, lung explants (mice), 293 CYP3A1, modulation of induction, polyinosinic acid-polycytidylic acid toxic and carcinogenic chemicals, bioactivation and detoxification, 1 (rats),520 Catalysts, oxidative drug metabolism studies, model systems, 811 CYP4A, subfamily gene products, pretranslational induction, reversal by Catechol-O-methyltransferase oral vanadate treatment (rats), 745 inhibitor entacapone, major metabolites (rats, humans), 81 Cysteamine-containing 2-(chloroethyl) nitrosoureas, main urinary me- inhibitor nitecapone, major metabolites (rats, dogs), 325 tabolites (rats, humans), 93 Cefadroxil, nonlinear pharmacokinetics (rats), 215 Cytochrome P-450 Cefcanel daloxate hydrochloride, disposition (humans), 171 lA family, inducibility ofenzyme activities, hepatocytes (human), 56 Cerebrospinal fluid, distribution of felbamate (rats), 1079 2B6, characterization, liver microsomes (humans), 1048 Chinese hamster ovary cells, pharmacokinetics, recombinant human bioactivation and detoxification, toxic and carcinogenic chemicals, 1 follicle-stimulating hormone (monkeys), 144 -catalyzed N-demethylation and 4-hydroxylation, tamoxifen metabo- 2-Chloro-l,l-difluoroethene, -facilitated metabolism, NADPH lism (rats), 645 and oxygen consumption, liver microsomes (rabbits), 299 enzymes and head injury (rats), 1064 l-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea, metabolites, carbamoy- flavin-containing monooxygenase and, biotransformation, 4-fluoro-N- lated thiol conjugates (rats, humans), 889 methylaniline, 218 2-(Chloroethyl) nitrosoureas inducers, biliary excretion of glutathione, hydrolysis products (rats), cysteamine-containing, main urinary metabolites (rats, humans), 93 342 orally administered mitozolomide, biodistribution and metabolism isozymes, hydroxylation ofdantrolene, liver microsomes (rats), 939 (mice), 560 liver microsomal, reductive metabolism, zonisamide (rats), 777 p-Chloronitrobenzene, pharmacokinetic study, acute poisoning (hu- -mediated dehydrogenation, 2-n-propyl-2(E)-pentenoic acid, liver mi- mans), 1142 crosomes (rats), 242 5-Chloro-3-phenylthioindole-2-carboxamide, biotransformation, potent metabolic N-demethylation, l,3-bis[[l-cycloheptyl-3-(p-dimethylami- HIV-1 reverse transcriptase inhibitor (monkeys, rats), 598 nophenyl)ureido) methyl)benzene dihydrochloride (rats), 524 Cholesterol, sulfation in liver (humans), 268 NADPH-cytochrome P-450 reductase and, reduction of 3’-azido-2’, Cholesterol acyltransferase, metabolic N-demethylation, l,3-bis[[l-cyclo- 3’deoxynucleosides, liver microsomes (rats), 946 heptyl-3-(p-dimethylaminophenyl)ureido] methyl)benzene dihy- regioselective contribution of 2D subfamily, metabolism, drochloride (rats), 524 liver microsomes (rats), 1012 CI-976, biodisposition studies (rats, monkeys), 1112 sex hormone-dependent, sulfamethazine as a model compound (rats), CI-941, see Biantrazole 441 Cigarette smoking, S-methamphetamine hydrochloride, pharmacoki- Cytochrome P-450 2El, liver microsomal defluorination (rats), netics (humans), 717 350 Cimetidine Cytochrome P-450 3A4, oxidation ofterfenadine, liver microsomes (hu- chemical, enzymatic, and enantioselective S-oxygenation (humans), mans), 403 587 Cytosol, aldehyde dehydrogenases, liver mitochondria, inhibition by inflammation and hypoxia, kinetics (rabbits), 7 crotonaldehyde (rats), 396 Cisplatin, reduction of nephrotoxicity, sodium selenite (mice, rats), 30 Clarithromycin, mixed function oxidase system, hepatic microsomes Dantrolene, hydroxylation, cytrochrome P.450 iozymes, liver micro- (rats), 358 somes (rats), 939 Qot,a.am, metabolic profiling (rats), 415 Dapsone Cobalt chloride, cobalt-protoporphyrin and, pharmacokinetics(rats), 846 inhibition of red blood cell N-acetyltransferase (humans), 181 Cocaine sulfamethoxazole and, N-chlorination, myeloperoxidase system, 830 hepatic biotransformation (guinea pigs), 390 Dehydroepiandrosterone sulfotransferase, cholesterol sulfation in liver inhibition ofmetabolism, benzoylecgomne and ecgonine methyl ester, (humans), 268 liver (mice, humans), 537 Deoxyribonuclease, recombinant human, altered pharmacokinetics, maternal/fetal plasma concentrations, transplacental pharmacoki- presence ofbinding protein (rats), 71 netics (monkeys), 364 Desferrioxamine, intravenous infusion pharmacokinetics, thalassemia Coenzyme A, metabolic inversion of(R)-ibuprofen (rats, humans), 114 (humans), 640 -speciflc Fab fragments, hepatic clearance (rats), 997 Desmethyipromethazine, oxidation, liver flavin-containing monooxy- Colon, uptake, 3- and 6-glucuronidation (guinea pigs), 13 genase (pigs), 24 Compartments, multicompartment model, terminal disposition half-life, Deuterium, substitution, inhibitory effects, metabolism mean residence time, 1172 (rats), 1170 Cotinine, rate of excretion in bile (rats), 927 Diabetes CQA 206-291, biotransformation, plasma clearance (humans, dogs, pharmacokinetics of zenarestat (rats), 677 rats), 454 pretranslational induction, CYP4A subfamily gene products, reversal Crotonaldehyde, inhibition, liver mitochondrial and cytosolic aldehyde by oral vanadate treatment (rats), 745 dehydrogenases (rats), 396 2,2-Dichloro-l,l,1-thfluorethane, liver microsomal metabolism (rats), Cunninghamella degans, microbial models of mammalian metabolism, 551 formation of glucoside, 259 l,l-Dichloroethylene, temporal effects, nonprotein sulfbydryl content, Cyclophosphamide, peroxidase-mediated metabolism (mice), 37 lung and liver (mice), 770 Cyclosporine, metabolism by liver microsomes (rats), 730 1,l-Dichloro-l-fluoroethane, gas-uptake pharmacokinetics, biotransfor- Cyclosporine A, bioavailability, effect ofatropine, gastrointestinal motH- mation (rats), 634 ity(rats), 141 Didanosine, absorption, disposition and metabolism (dogs), 447 1180 SUBJECT INDEX

2 ‘ ,3 ‘-Dideoxyadenosine-5 ‘-triphosphate, anomalous accumulation and Estradiol, caffeine and progesterone, interaction with CYP1A1 and decay, 2’,3’-dideoxyinosine exposure, T-cell cultures (humans), CYP1A2, Saccharomyces cerevisiae (human), 43 369 Ethanol, inhibition of cocaine metabolism, benzoylecgonine and ecgon- 2’,3’-Dideoxycytidine diphosphocholine, 2’,3’-dideoxycytidine diphos- inc methyl ester, liver (mice, humans), 537 phoethanolamine and, characterization, 738 Ethimizol, xanthine-related, nonlinear elimination, 3-methylcholan- 2’,3’-Dideoxyinosine threne-induced liver (rats), 547

anomalous accumulation and decay, 2 ‘ ,3 ‘-dideoxyadenosine-S ‘-#{252}i-Ethoxyresorufin O-dethylase, inducibility of enzyme activities, cyto- phosphate, T-cell cultures (humans), 369 chrome P-450 lA family, hepatocytes (human), 56 no metabolism in placenta (humans), 544 Exercise, treadmill, increased renal drug metabolism, Fischer-344 male N,N-Diethylbenzamide, N,N-diethyl-a,a’-’3C- and, metabo- rats,474 lism by liver microsomes (rats), 133 Fab fragments, colchicine-specific, hepatic clearance (rats), 997 Digestive enzymes, immobilized, application of assay, chemical and Famiciclovir, 6$-hydroxylation of testosterone, liver microsomes (hu- enzymatic hydrolysis oflysobactin, 573 mans), 18 Digitoxigenin monodigitoxoside, UDP-glucuronsyltransferase activity, Fatty acids, metabolic inversion of (R)-ibuprofen, formation, ibupro- liver microsomes (humans), 338 fenyl-coenzyme A (rats, humans), 114 Digitoxin, -glucuronidase-resistant glucuronide conjugate, liver micro- FCE 22 178, 5,6-dihydro-7-( 1H-imidazol- l-yl)-naphthalene-2-carboxylic somes (dogs), 1147 acid, in vivo glucuronidation (rats, humans), 151 5,6-Dihydro-7-( lH-imidazol-l-yl)-naphthalene-2-carboxylic acid, in vivo Felbamate glucuronidation (rats, humans), 151 distribution to cerebrospinal fluid and and brain (rats), 1079 Dihydropyndine, calcium antagonist SM-6586, cleavage, 1,2,4-oxadi- major urinary metabolite, 3-carbamoyloxy-2-phenylpropionic acid azolering, 1167 (humans), 710 Dihydropyrimidine amidohydrolase, enzymatic ring-opening reactions, Fetus ICRF-187 and ICRF-l86, 883 hepatic biotransformation ofcocaine (guinea pigs), 390 l,3-Di(4-imidazolino-2-methoxyphenoxy)propane, disposition (rats), maternal/fetal plasma concentrations of cocaine, transplacental phar- 1017 macokinetics (monkeys), 364 Diltiazem, disposition and negative dromotropic activity, effects of pro- FK 506 pranolol, multiple dosing (dogs), 156 disposition, role of red blood cell binding, hepatic clearance (rabbits), , disposition of, effect of propylene glycol (rabbits), 305 690 1,2-Dimethyl-3-hydroxypyridin-4-one, pharmacokinetics (rabbits), 255 isomerized epoxide metabolite, erythromycin-induced liver micro- 2,2-Dimethyl-N-(2,4,6-trimethoxyphenyl)dodecanamide, biodisposition somes (rabbits), 850 studies (rats, monkeys), 1112 oxidative metabolites (rats), 971 Diosmetin, glucuronidation (rats), 1157 Flame retardant, l,2-bis(2,4,6-tribromophenoxy)ethane, disposition fol- Diquat, redox cycling and hepatotoxicity, aging (rats), 605 lowing administration in diet (rats), 209 Ditekiren, hepatic elimination (rats), 184 Flavin DN-2327, see Pazinaclone -containing monooxygenase DNA, intercalator 502U83, pharmacokinetics and disposition (rats), 62 cytochromes P-450 and, biotransformation of 4-fluoro-N-methylan- DNA, complementary, Saccharomyces cerevisiae, interaction with iline, 218 CYPIA1 and CYPIA2, caffeine/estradiol/progesterone (human), enantioselective S-oxygenation, cimetidine (humans), 587 43 N-oxidation, tamoxifen metabolism (rats), 657 DNA adducts, bioactivation and detoxification, toxic and carcinogenic oxidation ofdesmethylpromethazine (pigs), 24 chemicals, 1 Flavoenzymes, microsomal, xanthine oxidase and, differential metabo- Doxorubicin, uptake in lungs, influence, temperature and plasma protein lism of merbazone (rats), 410 (rabbits), 428 Flavonoids, diosmetin, glucuronidation (rats), 1157 Dramamine, disposition of, effect of propylene glycol (rabbits), 305 Flumecinol, metabolism, fluorine NMR studies (rats), 105 Fluorine, NMR studies, metabolism offlumecinol (rats), 105 Ecgonine methyl ester, metabolism of cocaine, inhibition by ethanol 4-Fluoro-N-methylaniline, biotransformation, role of cytochromes P- (mice, humans), 537 450, flavin-containing monooxygenase, 218 Endonucleases, altered pharmacokinetics, recombinant human deoxyri- 5-Fluorouracil, bromodeoxyuridine or iododeoxyuridine, mutual kinetic bonuclease, presence of binding protein (rats), 71 interaction (dogs), 277 Endotoxemia, bacterial lipopolysaccharide, disposition and renal hand- Fluvastatin sodium, biotransformation (humans), 567 ling, enprofylline (rats), 611 Follicle-stimulating hormone, recombinant human, pharmacokinetics Enflurane, defluorination, cytochrome P-450 2E1 as major catalyst, liver (monkeys), 144 microsomes (rats), 350 Furosemide glucoside, formation, microbial models, mammalian metab- Enprofylline, disposition and renal handling, bacterial lipopolysaccha- olism, 259 ride, endotoxemia (rats), 611 Entacapone, catechol-O-methyltransferase inhibitor, major metabolites Gastrointestinal tract (rats, humans), 81 effect of atropine on motility, bioavailability of cyclosporine A (rats), Enzymes 141 hepatic drug metabolism, comparison, Phases I and II (humans, mon- morphine uptake, 3- and 6-glucuronithtion (guinea pigs), 13 keys), 753 Gene, UGT1, substrate specificities, liver UDP-glucuronosyltransferases, other than cytochrome P-450 3A, cyclosporine metabolism, liver 50 microsomes (rats), 730 fl-Glucuronidase Epoxide, isomerized metabolite of FK-506, erythromycin-induced liver in vivo glucuronidation, 5,6-dihydro-7-(1H-imidazol-l-yl)-naphtha- microsomes (rabbits), 850 lene-2-carboxylic acid (rats, humans), 151 Ergot, derivative CQA 206-291, biotransformation, plasma clearance -resistant glucuronide conjugate ofdigitoxin, liver microsomes (dogs), (humans, dogs, rats), 454 1147 Erythromycin-induced liver microsomes, isomerized epoxide metabolite, ‘y-Glutamyltranspeptidase, glutathione and hydrolysis products, biliary FK-506 (rabbits), 850 excretion, effect of P-450 inducers (rats), 342 SUBJECT INDEX 1181

Glutathione Isoflurane-facilitated 2-chloro-1,l-difluoroethene metabolism, NADPH conjugation activities toward bromosulfophthalein, perfused liver and oxygen consumption, liver microsomes (rabbits), 299 (rats), 1070 Ketoprofen glucuronide, in vitro irreversible binding, plasma proteins hydrolysis products and, biliary excretion, effect of P-450 inducers (rats), 617 (rats), 342 Kidney reaction of meiphalan, kinetic analysis (humans), 986 arsenite effects, NAD(P)H:quinone acceptor oxidoreductase (rats), 334 Glycoaldehyde, metabolism by liver microsomes, N,N-diethyl-a,a’-’3C- diposition and handling of enprofylline, bacterial lipopolysaccharide, benzamide, N,N-diethylbenzamide (rats), 133 endotoxemia (rats), 61 1 Gonadotropin-releasing hormone, 3H-labeled, disposition, buserelin failure, pharmacokinetic properties, BM 06.022 (rats), 236 (rats), 818 increased drug metabolism, treadmill-exercised Fischer-344 male rats, Guengerich, F. Peter, 1992 Bernard B. Brodie Award Lecture, bioacti- 474 vation and detoxification, toxic and carcinogenic chemicals, 1 membrane vesicle preparations, inhibition ofsulfate transport, nonste- Gut, disposition of morphine, 3- and 6-glucuronide metabolites (sheep), roidal antiinflammatory drugs (rats), 750 1151 targeting of 6-mercaptopurine (rats), 841 Halothane, biotransformation, concentration-dependent inhibition L-158,338, 1,2-hydride shift in microsomal metabolism (rats), 670 (guinea pigs), 386 L-69l,l2l, metabolism studies, class III antiarrhythmic agent (dogs), 467 Head, injury, cytochrome P-450 enzymes (rats), 1064 Labetalol, disposition and metabolism, pharmacodynamics (sheep), 284 Heart (R),(R)-Labetalol, indolic metabolite (monkeys), 198 arsenite effects, NAD(P)H:quinone acceptor oxidoreductase (rats), 334 Lactone, FK 506, oxidative metabolites (rats), 971 tirilazad disposition (rats), 951 Lipids, metabolic inversion of (R)-ibuprofen, formation, ibuprofenyl- Hepatocytes coenzyme A (rats, humans), 1 14 inducibility of enzyme activities, cytochrome P-450 1A family (hu- Lipophilicity, hepatic dispersion and, homologous series of barbiturates, man), 56 liver (rats), 933 stereochemical studies, fl-oxidation, valproic acid (rats), 580 Lipopolysaccharide, bacterial, disposition and renal handling, endotox- Hepatotoxicity, redox cycling and, diquat, aging (rats), 605 emia (rats), 611 Hep G2 cells, stereoselective sulfation of albuterol (humans), 76 Liver Histamine, oxidation ofterfenadine, liver microsomes (humans), 403 N-acetylation polymorphism (rats), 965 Human immunodeficiency virus arsenite effects, NAD(P)H:quinone acceptor oxidoreductase (rats), 334 2’,3’-dideoxycytidine diphosphocholine, 2’,3’-dideoxycytidine di- aryl sulfotransferase IV, naphthaldehydes as reversible inhibitors (rats), phosphoethanolamine, characterization, 738 400 2’,3’-dideoxyinosine exposure of T-cells, anomalous accumulation biotransformation and decay, 2’,3’-dideoxyadenosine-5’-triphosphate (humans), cocaine (guinea pigs), 390 369 plasma clearance and, CQA 206-291 (humans, dogs, rats), 454 Human immunodeficiency virus-l proterguride (rats), 203 metabolism and disposition, thiazolobenzimidazole (mice), 231 caffeine metabolism, postnatal development (rats), 178 reverse transcriptase inhibitor, biotransformation, 5-chloro-3-phenyl- cholesterol sulfation (humans), 268 thioindole-2-carboxamide (monkeys, rats), 598 clearance, colchicine-specific Fab fragments (rats), 997 Hydrocarbons, polyaromatic, arsenite effects, NAD(P)H:quinone accep- CYP3A1 induction, modulation, polyinosinic acid-polycytidylic acid tor oxidoreductase activity, various organs (rats), 334 (rats), 520 3-Hydroxycotinine glucuronide, rate ofexcretion in bile (rats), 927 disposition of morphine, 3- and 6-glucuronide metabolites (sheep), 3-Hydroxypyridin-4-ones, pharmacokinetics (rabbits), 255 1151 Hypocalcemia, hypercalcemia and, uptake of alendronate, bone tissue disturbances, propofol kinetics (rabbits), 7 (rats),800 drug metabolism, Phases I and II, comparison (humans, monkeys),

Hypouricemi . differential metabolism of merbazone, xanthine oxidase, 753 microsomal flavoenzymes (rats), 410 effect of P-450 inducers, biiary excretion, glutathione and its hydrol- Hypoxia, cimetidine and inflammation, propofol kinetics (rabbits), 7 ysis products (rats), 342 elimination of ditekiren (rats), 184 (R)-Ibuprofen, metabolic inversion, formation of ibuprofenyl-coenzyme extra.hepatic metabolism and, salbutamol (rabbits), 485 A (rats, humans), 114 failure, pharmacokinetic properties, BM 06.022 (rats), 236 Ibuprofenyl-coenzyme A, formation, metabolic inversion of(R)-ibupro- flavin-containing monooxygenase, oxidation of desmethylprometha- fen (rats, humans), 114 (pigs), 24 ICRF-187, ICRF-186 and, enzymatic ring-opening reactions, dihydro- fluorine NMR studies, flumecinol metabolism (rats), 105 pyrimidine amidohydrolase, 883 inhibition by ethanol, metabolism of cocaine, benzoylecgonine and Idapril, pharmacokinetics and pharmacodynamics (rats, dogs, humans), ecgonine methyl ester (mice, humans), 537 835 in situ perfused, carbovir disposition (rats), 724 Incubation system, metabolism studies, precision-cut liver slices (rats), lipophilicity and hepatic dispersion, homologous series of barbiturates 699 (rats), 933 Inflammation, cimetidine and kinetics, propofol kinetics (rabbits), 7 localization ofglutathione conjugation activities, bromosulfophthalein Interferon, inducer polyinosinic acid-polycytidylic acid, modulation, he- (rats), 1070 patic CYP3A1 induction (rats), 520 mitochondrial and cytosolic aldehyde dehydrogenases, inhibition by Intestine crotonaldehyde (rats), 396 morphine uptake, 3- and 6-glucuromdation (guinea pigs), 13 morphine uptake, 3- and 6-glucuronidation (guinea pigs), 13 vasculature preparations, carbovir disposition (rats), 724 nonprotein sulthydryl content, temporal effects, 1,1-dichloroethylene Iododeoxyuridine, 5-fluorouracil and bromodeoxyuridine, mutual ki- (mice), 770 netic interaction (dogs), 277 pharmacokinetics, zidovudine bioavailabiity (mice), 189 Iron chelators, pharmacokinetics of 3-hydroxypyridin-4-ones (rabbits), precision-cut slices 255 simple incubation system, metabolism studies (rats), 699 1182 SUBJECT INDEX

tolbutamide metabolism (rats, dogs), 705 Maturation, postnatal development, caffeine metabolism, liver slices samples obtained as surgical waste, kinetic characterization, S-me- (rats),178 phenytoin 4-hydroxylase (humans), 747 Melphalan, reaction with water, phosphate and glutathione, kinetic tirilazad disposition (rats), 951 analysis (humans), 986 UDP-glucuronosyltransferases, substrate specificities, UGT1 gene fam- S-Mephenytoin 4-hydroxylase, kinetic characterization of activity, liver ily, 50 samples obtained as surgical waste (humans), 747 Liver microsomes Merbazone, differential metabolism, xanthine oxidase and microsomal angiotensin II antagonists, tetrazole N-glucuronidation (rats, flavoenzymes (rats),410 dogs, monkeys, humans), 792 6-Mercaptopurine, targeting to kidneys (rats), 841 bioactivation and irreversible binding, tacrine (humans, rats), 874 Metabolism studies, simple incubation system, precision-cut liver slices biotransformation of 5-chloro-3-phenylthioindole-2-carboxamide, po- (rats), 699 tent HIV-l reverse transcriptase inhibitor (monkeys, rats), 598 Metalloporphyrins, water-soluble, oxidative drug metaboilsm studies, characterization, cytochrome P-450 2B6 (humans), 1048 model systems, 81 1 cyclosporine metabolism (rats), 730 Methamphetamine, self-administration by smoking, pharmacokinetics cytochrome P-450, reductive metabolism, zonisamide (rats), 777 (humans), 717 cytochrome P-450-mediated dehydrogenation, 2-n-propyl-2(E)-pen- Methoxyresorufin, inducibility of enzyme activities, cytochrome P450 tenoic acid (rats), 242 1A family, iepatocytes (human), 56 enflurane defluorination, cytochrome P450 2El as major catalyst 3-Methylcholanthrene, -induced liver, nonlinear elimination, xanthine- (rats), 350 related ethimizol (rats), 547 erythromycin-induced, isomerized epoxide metabolite, FK-506 (rab- 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone bits), 850 effect of tobacco smoke condensate on metabolism, adult and fetal fractions, CYP3A-mediated N-deethylation, amiodarone (humans), microsomes (hamsters), 318 978 metabolism in lung explants, inhibitory effects, NSAIDS (mice), 293 $-glucuronidase-resistantglucuronide conjugate, digitoxin (dogs), 1147 lla-Methyltestosterone, biotransformation and branchial excretion glucuronidation of 3’-azido-3’-deoxythymidine, effect, anticancer (fish), 377 drugs (humans), 823 Metoprolol, enantioselective oxidative metabolism, inhibition by vera- 1,2-hydride shift, metabolism of L-l 58,338 (rats), 670 pamil, liver microsomes (humans), 309 hydroxylation ofdantrolene, cytochrome P-450 isozymes (rats), 939 Microbes, Cunninghamella elegans, formation of furosemide glucoside, 6-hydroxylation oftestosterone, famiciclovir (humans), 18 259 inhibition by , enantioselective oxidative metabolism, me- toprolol (humans), 309 Microsomes metabolism of 2,2-dichloro-l,l,1-thfluorethane (rats), 551 adrenal, monooxygenase, zonal differences in thermal lability (guinea metabolism of N,N-diethylbenzamide, N,N-diethyl-a,a’-’3C-benza- pigs), 200 mide(rats), 133 adult and fetal, effects of tobacco smoke condensate, 4-(methylnitro- mixed function oxidase system, effects of clarithromycin (rats), 358 samino)-l-(3-pyridyl)-l-butanone (hamsters), 318 NADPH and oxygen consumption, isoflurane-facilitated 2-chloro-l,l- , drug metabolism studies, “intrinsic” and “extrinsic” labels difluoroethene metabolism (rabbits), 299 (dogs), 868 9-naphthoflavone, verlukast metabolites, epoxide intermediate (rats, Mitochondria, hepatic, cytosolic aldehyde dehydrogenase and, inhibition mice), 861 by crotonaldehyde (rats), 396 ortho chlorine substituents, metabolism of4-toluidines, 508 Mitozolomide, orally administered, biodistribution and metabolism oxidation ofterfenadine (humans), 403 (mice), 560 oxidative metabolites of FK506 (rats), 971 Mixed function oxidase system, effects ofclarithromycin, hepatic micro- propranolol metabolism, regioselective contribution, cytochrome P- somes (rats),358 450 2D subfamily (rats), 1012 Models, multicompartment, terminal disposition half-life, mean red- quantitation of butadiene metabolites (rats), 121 dence time, 1172 stereo- and regioselective N- and S-oxidation, tertiary amines and Monooxygenases sulfides (humans), 492 adrenal microsomal, zonal differences, thermal lability (guinea pigs), I digitoxigenin monodigitoxoside 200 (humans), 338 flavin-containing Lovastatin, biotransformation, species differences (mice, rats, dogs, hu- cytochromes P450 and, biotransformation of 4-fluoro-N-methylan- mans), 1003 iline, 218 Lung oxidation ofdesmethylpromethazine, liver (pigs), 24 arsenite effects, NAD(P)H:quinone acceptor oxidoreductase (rats), 334 metabolic N-demethylation, l,3-bis[[l-cycloheptyl-3-(p-dimethylami- doxorubicin uptake, influence, temperature and plasma protein (rab- nophenyl)ureido] methyljbenzene dihydrochloride (rats), 524 bits), 428 stereo- and regioselective N- and S-oxidation, tertiary amines and metabolism of4-(methylthtrosamino)-1-(3-pyridyl)-l-butanone, inhib- sulfides, liver microsomes (humans), 492 itory effects, NSAIDS (mice), 293 Morphine nonprotein sulfhydryl content, temporal effects, l,l-dichloroethylene 3- and 6-glucuronide metabolites, disposition, morphine infusion (mice), 770 (sheep), 1151 LY2 17896, see 1,3,4-Thiadiazol-2-ylcyanamide uptake and 3- and 6-glucuronidation, stomach and intestine, colon Lysobactin, chemical and enzymatic hydrolysis, application, immobi- and liver (guinea pigs), 13 lized digestive enzyme assay, 573 Multiple indicator dilution technique, localization of glutathione conju- Macrolide, lactone FK506, oxidative metabolites (rats), 971 gation activities, bromosulfophthalein (rats), 1070 N-Mandelyl-2-aminoethanol, oral [‘4C]cefcanel daloxate hydrochloride Mycodysplasia, pharmacokinetics of 3-hydroxypyridin-4-ones (rabbits), disposition (humans), 171 255 Mass spectrometry, drug metabolism studies, “intrinsic” and “extrinsic” Myeloperoxidase, system, N-chlorination, sulfamethoxazole and dap- labels, midazolam (dogs), 868 sone, 830 SUBJECT INDEX 1183

NADPH, oxygen consumption and, isoflurane-facilitated 2-chloro-1,l- Polyinosinic acid-polycytidylic acid, modulation, hepatic CYP3A1 in- difluoroethene metabolism, liver microsomes (rabbits), 299 duction (rats), 520 NAD(P)H:quinone acceptor oxidoreductase, effects ofarsemte, liver and Pregnancy lung, heart and kidney (rats), 334 hepatic biotransformation ofcocaine (guinea pigs), 390 Naphthaldehydes, reversible inhibitors, hepatic aryl sulfotransferase N maternal/fetal plasma concentrations of cocaine, transplacental phar- (rats), 400 macokinetics (monkeys), 364 -Naphthoflavone Progesterone, caffeine and estradiol, interaction with CYP1A1 and arsenite effects, NAD(P)H:quinone acceptor oxidoreductase activity, CYP1A2, Saccharomes cerevisiae (human), 43 various organs (rats), 334 Propofol, kinetics, effect of cimetidine, inflammation and hypoxia (rab- verlukast metabolites, epoxide intermediate, hepatic microsomes (rats, bits), 7 mice), 861 Propranolol Nasal tissue, carboxylesterase-mediated metabolism, kinetics, vinyl ace- disposition and negative dromotropic activity, diltiazem, multiple tate (rats),1 107 dosing (dogs), 156 , pharmacokinetics, bioavailability and disposition (dogs), metabolism in liver microsomes, regioselective contribution, cyto- 502 chrome P450 2D subfamily (rats), 1012 Nephrotoxicity, cisplatin, reduction, sodium selenite (mice, rats), 30 Propylene glycol, disposition of Dramamine (rabbits), 305 Nicotine glucuronide, rate ofexcretion in bile (rats), 927 2-n-Propyl-2(E)-pentenoic acid, cytochrome P-450-mediated dehydro- Nitecapone, identification of major metabolites (rats, dogs), 325 genation, liver microsomes (rats), 242 Nitric oxide, nitrite ion not an active intermediate, vascular metabolism, Prostaglandin H synthase, peroxidase-mediated metabolism, cyclophos- organic nitrates and organic nitrites, 967 phamide (mice), 37 P-Nitro-L-arginine, pharmacokinetics (rats), 962 Proteases, digestive, degradation oflysobactin, 573 Nonsteroidal antiinflammatory drugs Proteins, polyethylene glycol-derivatized, strategy for characterization, inhibition of sulfate transport, kidney membrane vesicle preparations 911 (rats),750 Proterguride, biotransformation in liver (rats), 203 inhibitory effects, metabolism of 4-(methylnitrosamino)-l-(3-pyridyl)- Protoporphyrin-cobalt and cobalt chloride, pharmacokinetics (rats), 846 1-butanone, lung explants (mice), 293 Pseudohexapeptide, ream inhibitor, hepatic elimination, ditekiren (rats), Nuclear magnetic resonance, fluorine, flumecinol metabolism (rats), 105 184

Obesity, nutritional, induction ofCYP2B enzymes, phenobarbital treat- Ractopamine hydrochloride, metabolism and disposition (turkeys), 624 ment (rats),782 Receptors l,2,4-Oxadiazole, cleavage ofring, metabolism of SM-6586, 1167 angiotensin II , metabolism and elimination (mice), 918 antagonists, tetrazole N-glucurothdation in hepatic microsomes Oxygen (rats, dogs, monkeys, humans), 792 consumption and NADPH, isoflurane-facilitated 2-chloro-l,1-difluo- nonpeptide antagonist L-158,338, 1,2-hydride shift in microsomal roethene metabolism, liver microsomes (rabbits), 299 metabolism (rats), 670 oxidative drug metabolism studies, model systems, 811 5-HT3, antagonist zatosetron (humans), 249 Pafenolol, presystemic elimination, pharmacokinetics and metabolism Red blood cells (rats,humans), 435 inhibition ofN-acetyltransferase (humans), 181 Pamidronate, 4-hour and 24-hour infusions, clearance and tissue uptake role ofbinding in hepatic clearance, disposition of tacrolimus (rabbits), (rats), 100 690 Pancreas, N-acetylation polymorphism (rats), 965 Refrigerants, biotransformation of halothane, concentration-dependent Pazinaclone, stereoselective metabolites (dogs), 805 inhibition (guinea pigs), 386 Peroxidase-mediated metabolism ofcyclophosphamide (mice), 37 Renin, inhibitor pseudohexapeptide, ditekiren, hepatic elimination (rats), Phencycidine, pharmacokinetics of phenylcyclohexyldiethylamine 184 (rats), 125 , absorption and metabolism, excretion (humans), 1134 Phenobarbital RNA, messenger, head injury and cytochrome P450 enzymes (rats), acute administration, disposition ofacetaminophen metabolites (rats), 1064 1129 DL-Rolipram, biotransformation, metabolites from wine (rats, monkeys, induction ofCYP2B enzymes, nutritional obesity (rats), 782 humans), 682 Phenols, liver UDP-glucuronosyltransferases, substrate specificities, UGT1 gene family, 50 Saccharomyces cerevisiae, cDNA-directed expression, interaction with Phenylcyclohexyldiethylamine, pharmacokinetics (rats), 125 CYP1A1 and CYP1A2, caffeine/estradiol/progesterone (human), Phosphate, reaction ofmelphalan, kinetic analysis (humans), 986 43 Phosphodiesters, 2’,3’-dideoxycytidine diphosphocholine, 2’,3’-dideox- Salbutamol, hepatic and extrahepatic metabolism (rabbits), 485 ycytidine diphosphoethanolamine, characterization, 738 Salicylazosulfapyridine, its metabolites and, toxicokinetics (mice), 1091 Placenta, no metabolism of 2’,3’-dideoxyinosine (humans), 544 Salmeterol xinafoate, disposition (rats, humans), 1022 Plasma Sanguinarmne, biometabolic elimination, organ retention profile (rats, clearance, biotransformation, CQA 206-291 (humans, dogs, rats), 454 guinea pigs), 194 protein and temperature, doxorubicin uptake, lungs (rabbits), 428 L-734,005, see 5-Chloro-3-phenylthioindole-2-carboxamide proteins, in vitro irreversible binding, ketoprofen glucuronide (rats), Sematilide, comparative kinetics (rats, rabbits, dogs, humans), 662 617 Sevoflurane, metabolism, inhibitory effects, deuteurium substitution tirilazaddisposition (rats), 951 (rats), 1170 Plasminogen activator, BM 06.022, pharmacokinetic properties, influ- Sex differences, tolbutamide metabolism, precision-cut liver slices (rats, ence of hepatic and renal failure (rats), 236 dogs), 705 Poisoning, acute, pharmacokinetic study, p-chloronitrobenzene (hu- Sex hormone-dependent cytochrome P450, sulfamethazine as a model mans), 1142 compound (rats), 441 Polyethylene glycol, -derivatized proteins, strategy for characterization, SM-6586, metabolism, cleavage, 1,2,4-oxadiazole ring, 1167 911 Sodium selenite, reduction of cisplatin nephrotoxicity (mice, rats), 30 1184 SUBJECT INDEX

Species differences, biotransformation of lovastatin (mice, rats, dogs, Tobacco smoke condensate, metabolism of 4-(methylnitrosamino)-l-(3- humans), 1003 pyridyl)-l-butanone, adult and fetal microsomes (hamsters), 318 Spironolactone, metabolites in plasma and target organs (guinea pigs), Tolbutamide, metabolism in precision-cut liver slices, qualitative and 1086 quantitative sex differences (rats, dogs), 705 Stomach, morphine uptake, 3- and 6-glucuronidation (guinea pigs), 13 4-Toluidines, microsomal metabolism, ortho chlorine substituents, 508 Substrates, oxidative drug metabolism studies, model systems, 811 3-Trifluoromethyl-a-ethylbenzhydrol, see Flumecinol Sulfamethazine, model compound, sex hormone-dependent cytochrome Tyrosine-ester sulfotransferase, naphthaldehydes as reversible inhibitors, P450 activity (rats), 441 hepatic aryl sulfotransferase IV (rats), 400 Sulfamethoxazole, dapsone and, N-chlorination, myeloperoxidase sys- 502U83, DNA intercalator, pharmacokinetics and disposition (rats), 62 tem, 830 U71038, see Ditekiren Sulfasalazine, its metabolites and, toxicokinetics (mice), 1091 U74006F, see Tirilazad Sulfate, inhibition of transport, kidney membrane vesicle preparations, UDP-glucuronsyltransferase nonsteroidal antiinflammatory drugs (rats), 750 activity toward digitoxigenin monodigitoxoside, liver microsomes(hu- Sulihydryl, nonprotein content of lung and liver, temporal effects, 1,1- mans), 338 dichloroethylene (mice), 770 liver, substrate specificities, UGT1 gene family, 50 Sulindac, inhibitory effects on carcinogen metabolism, lung explants Urine (mice), 293 metabolites, biotransformation of DL-rolipram (rats, monkeys, hu- , disposition (rats, mice, dogs, rabbits, humans), 761 mans), 682 Tacrine, bioactivation and irreversible binding, liver microsomes (hu- metabolites ofbiantrazole, detection and identification (humans), 955 mans, rats), 874 Valproic acid Tacrolimus, see FK 506 4-ene VPA and 4-pentenoic acid, reactive metabolites, thiol conjugates, Tamoxifen 1098 metabolism, cytochrome P450-catalyzed N-demethylation, 4-hydrox- 2-n-propyl-2(E)-pentenoic acid, cytochrome P450-mediated dehydro- ylation (rats),645, 657 genation, liver microsomes (rats), 242 phase I and phase II metabolites, breast cancer (humans), 1119 9-oxidation, stereochemical studies, hepatocytes (rats), 580 T-cdlls, anomalous accumulation and decay, 2’,3’-dideoxyadenosine-5’- Vanadate, oral treatment, pretranslational induction, CYP4A subfamily triphosphate, 2’,3’-dideoxyinosine exposure (humans), 369 gene products (rats),745 Temperature, plasma protein and, doxorubicin uptake, lungs (rabbits), Velnacrmne maleate, disposition (rats, dogs, humans), 1037 428 Verapamil, inhibition, enantioselective oxidative metabolism of meto- Terfenadine, oxidation in liver microsomes (humans), 403 prolol, liver microsomes (humans), 309 Testicles, spironolactone metabolites, plasma and target organs (guinea Verlukast pigs),1086 epoxidation, CYP1A1 specificity (mice, rats, monkeys, humans), 1029 Testosterone metabolites arising from an epoxide intermediate, 9-naphthoflavone, 6fi-hydroxylation, famiciclovir, liver microsomes (humans), 18 hepatic microsomes (rats, mice), 861 pharmacokinetics ofzenarestat, diabetes (rats), 677 Vigabatrin, pharmacokinetics and metabolism (humans), 480 Tetrazole, N-glururonidation, angiotensin II receptorantagonists, hepatic Vinyl acetate, carboxylesterase-mediated metabolism, kinetics (rats), microsomes (rats, dogs, monkeys, humans), 792 1107 Thalassemia, intravenous infusion pharmacokinetics, desferrioxamine Water, reaction of melphalan, kinetic analysis (humans), 986 (humans), 640 $-Thalassemia, pharmacokinetics of 3-hydroxypyridin-4-ones (rabbits), Xanthine-related drug ethimizol, nonlinear elimination, 3-methylchol- 255 anthrene-induced liver (rats), 547 l,3,4-Thiadiazol-2-ylcyanamide, biotransformation, characteristics, me- Xanthine oxidase, microsomal flavoenzymes and, differential metabo- soionic ribose metabolite (mice), 162 lism, merbazone (rats), 410 Thiazolulbenzimidazole, metabolism and disposition, activity against Xenobiotics HIV-1 (mice), 231 CYP1A1 specificity, verlukast epoxidation (mice, rats, monkeys, hu- Thiol mans), 1029 carbamoylate conjugates, metabolites of 142-chloroethyl)-3-cycloh- metabolic inversion of (R)-ibuprofen, formation, ibuprofenyl-coen- exyl-l-nitrosourea (rats, humans), 889 zyme A (rats, humans), 114 conjugates of reactive metabolites, 4-ene VPA and 4-pentenoic acid, Zatosetron, disposition (humans), 249 1098 Zenarestat, pharmacokinetics, diabetes (rats), 677 Thromboxane synthase, inhibitor 5,6-dihydro-7-(lH-imidazol-1-yl)- Zidovudine, bioavailability and liver pharmacokinetics (mice), 189 naphthalene-2-carboxylic acid, in vivo glucuronidation (rats, hu- Zonisamide, reductive metabolism, liver microsomal cytochrome P450 mans), 151 (rats), 777 Tirilazad, disposition, plasma and heart, brain and liver (rats), 951 Zopiclone, its enantiomers and, pharmacokinetics (humans), 1125 Copyright © 1993 by The American Society for Pharmacology and Experimental Therapeutics The top ranking journal in the field... Pharmacological

A Publication ofthe American Society for Pharmacology and Experimental Therapeutics, Inc.

Robert E. Stitzel, PhD, Editor West Virginia University Medical Center

P harmacological Reviews is a show-case for importantreview articles in your field, featuring more comprehensive papers on topics of high current interest.

The Journal continues to publish the important, longer papers of interest to pharmacologists, physiologists, toxicologists, and biological chemists. No library serving the pharmacologist should be without a subscription.

Published Quarterly

Discounts available to members on all ASPET publications. Save 10% when ordering two Save 15% when ordering three Save 20% when ordering four #{149}:#{149}

I Please enter my subscription to Pharmacological Reviews. Payment Options: () I I :i Check enclosed (payable to Williams & Wilkins) I Individual $60/year J Bill me J American Express MasterCard VISA I :i Institutional $107/year Card # Exp. date ______

I i Intraining* $45/year Signature or P.O. # ______I

I (add $15/year outside the U.S.; in Canada also add 7% GST) MD and PA subscribers must add state sales tax. Subscriptions outside I I New Subscription 1 Renewal the U.S. must be prepaid in U.S. dollars. In Japan, contact Igaku-Shoin. : Subscribe for: El 3 years J 2 years 1 1 year MYW. Ltd. (03) 5689-5400. Rates valid through October 31, 1994. I Return coupon to:

IName ______.. . I Address ______Williams & Wllklns I . . A WAVERLY COMPANY City/StateP LLI) #{149} #{149}. P.O. Box 23291. Baltimore, MD 21203-9990

I * Please indicate institution/status I For credit card orders, call TOLL FREE: I 1-800-638-6423 in the U.S. or Canada. L__vrs 55077 Printed n (iSA J4077S ZPT,,J MOLECULAR PHARM

Editor: T. Kendall Harden, PhD, University of North Carolina School of Medicine, Chapel Hill, North Carolina Is ‘our special interest receptors and neurotransmitters . . . drug

metabolism . . . antibiotic and anticancer drug actions . . . or other

voLpJ(: 4. areas related to the molecular basis ofdrug action? Ifso, you 4CM#{216}f1 should he subscribing to MOLECULAR PHARMACOLOGY. .:ijp4 The editor’s and editorial board’s high standards ensure that the papers you read in MOLECULAR PHARMACOLOGY are on the cutting edge ofresearch on drug action and selective toxicity at the molecular level. Original applications of biochemistry, biophysics, genetics, and molecular biology arejuxtaposed with innovative pharmacologic research to elucidate basic problems in pharma- cologv and toxicology, including such areas as molecular mecha- nisms involved in drug receptor-effector coupling, xenobiotic metabolism, and antibiotic and anticancer drug action. Start your subscription today to ensure access to the most newsworthy papers inyour field. Month lv Call toll-free to start your subscription immediately, 1-800-638-6423 fromanywhere in the ITS. or Canada.

r ------ - - - -

Avoid luture rate increases arl ensure uninterruptcd scr’.ie--enter Payment options. our niultivear SLII)sTiption today E Chek eii1osed Bill e E \ISA E lasterCard E Anierian Express Molecular Phannacolgy ( ili)ntlllv) lnlik1ua1: $ LOS yr Institutions: 23O i arj

(IIea.e (k/(/S)’UO() ()l1t.cl/’ the ( IS. in (,icic1a. alco aiki ‘ GST ______E N(.\v E Rene:d E 3 ‘is E 2 \rs E 1 igiiatirc P 0

MD and PA subscribers must add state sales tax. Subscriptions from outside the IJS and Canada must be prepaid. in US dollars o,t/v. In Japan. contact Igaku-Shoin MYW Ltd. (03) 5689-54(X). Rates valtd for orders received through October 31. 11.It1k l9)4.

______Please allow S v’ceks tor delivers 0) your first issue. Surface mail dcliser to .iddrcs countries outside the LTS nia take up to 1( ssecks. Airmail rates available upon request.

its t.itt#{149}/1)) Discounts available to members on all ASPET publications. SAVE a hen ordering t\’O. SAVE 1( when ordering three. SAVE 2U? when ordering all tour. \\,T jjj . :: jJj i o Box 22) 1 Rn tJx .tv H& USC B.IItit()re. sIjr land . 1.i3 9Q5) 2U Ii1hantBroajas L&iiidoii \‘i#{149}( IA.A Eng1ati A WAVERLY COMPANY MOL 55049 Printed in USA J4049S ZMOL